William Blair & Company’s Recursion Pharmaceuticals RXRX Stock Holding History

William Blair & Company’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$92.3K	Sell	30,061 -43,939	-59%	-$170K	﹤0.01%	1605
2025 Q4	$303K	Sell	74,000 -3,033	-4%	-$15K	﹤0.01%	1307
2025 Q3	$376K	Buy	77,033 +33	+0%	+$173	﹤0.01%	1216
2025 Q2	$390K	Sell	77,000 -37,500	-33%	-$184K	﹤0.01%	1163
2025 Q1	$606K	Buy	114,500 +102,500	+854%	+$747K	﹤0.01%	1033
2024 Q4	$81.1K	Buy	+12,000	New	+$80.7K	﹤0.01%	1551

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

William Blair & Company's RXRX Position: Q1 2026 in Review

William Blair & Company reduced its Recursion Pharmaceuticals (RXRX) stake by 59% in Q1 2026, selling an estimated $170K and leaving 30,061 shares worth $92.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1605.

William Blair & Company first reported a position in RXRX in Q4 2024 and has held it in 6 quarters since. The position peaked at $606K in Q1 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

William Blair & Company held 30,061 shares of Recursion Pharmaceuticals worth $92.3K as of Q1 2026.
William Blair & Company sold 43,939 Recursion Pharmaceuticals shares in Q1 2026, an estimated $170K.
Recursion Pharmaceuticals made up ﹤0.01% of William Blair & Company's portfolio in Q1 2026, its #1605 holding.
William Blair & Company first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
William Blair & Company's Recursion Pharmaceuticals position peaked at $606K in Q1 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.